Samsung Bioepis Is A Biopharmaceutical Company Focused On Developing And Commercializing Biosimilarswhich Are Biologic Drugs That Closely Resemble Existing Biologic Medicationsestablished In 2012 As A Joint Venture Between Samsung Biologics And Biogenthe Company Became A Wholly Owned Subsidiary Of Samsung Biologics In 2022Its Mission Is To Enhance Patient Access To High Quality Medicines Through Innovative Science And Technology The Company Specializes In Biosimilar Developmentensuring That Its Products Meet High Standards Of Qualitysafetyand Efficacysamsung Bioepis Collaborates With Partners Like Biogen And Organon To Market Its Biosimilars Globallynotable Products Include Opuvizrecently Approved By The European Commissionalong With Other Biosimilars Targeting Conditions Such As Rheumatoid Arthritis And Cancerthrough Its Strategic Partnerships And Commitment To Innovationsamsung Bioepis Aims To Expand Access To Affordable Biologic Therapies Worldwide
